Compare Abeona Therapeutics Inc (ABEO) vs Under Armour Inc Class A (UA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Under Armour Inc Class A trades at $6.31 (market cap $2.84B). The key difference: Under Armour Inc Class A is far larger — about 7.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ABEO | UA | |
|---|---|---|
Market Cap | $373.32M | $2.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $7.88 |
52-Week Low | $4.17 | $3.96 |
Enterprise Value | $228.22M | $4.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Under Armour (UA) trades at $6.64, up 2.47% with a bullish technical signal from moving averages despite bearish oscillators. The company reported mixed Q1 2026 results, missing EPS expectations after beating in previous quarters. Revenue declined to $5.0B in 2026 with a net loss of -$496M, though valuation remains reasonable with P/S of 0.57. Recent news highlights a Dodge collaboration and insider buying by Prem Watsa.
The outlook remains challenging with declining revenue and negative profitability, but analyst consensus leans positive with 40% buy ratings. Key risks include sustained revenue declines and competitive pressures, while potential catalysts include premium product focus and inventory discipline. The stock presents a turnaround opportunity with significant execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
